p16^(INK4a)对宫颈癌患者的早期筛查效果研究

Performance of p16^(INK4a) for detection of cervical cancer early

目的探讨p16^(INK4a)对宫颈癌患者的早期筛查效果。方法选取2017年10月至2019年10月间北京百子湾和美妇儿医院收治的80例宫颈癌患者,根据检测方式不同分为观察组和对照组,每组40例。对照组患者采用液基细胞学检测(LCT),观察组患者采用LCT联合p16INK4a检测,比较两组患者细胞学诊断结果与病理检测结果符合率。结果两组患者的非典型鳞状细胞(ASC)和无上皮内病变或恶性病变(NILM)诊断符合率比较,差异无统计学意义(P>0.05);鳞状细胞癌(SCC)、高度鳞状上皮内病变(HSIL)和低度鳞状上皮内病变(LSIL)诊断符合率比较,差异均有统计学意义(均P<0.05)。两组患者宫颈上皮内瘤变(CNI)Ⅰ和炎症诊断符合率比较,差异无统计学意义(P>0.05);SCC、CINⅢ和CINⅡ诊断符合率比较,差异均有统计学意义(均P<0.05)。结论LCT联合p16^(INK4a)检测宫颈癌诊断率与病理诊断符合率较高,值得临床推广使用,以提高宫颈癌早期诊断率。

Objective To explore the performance of p16^(INK4a) for detection of cervical cancer early.Methods From October 2017 to October 2019,80 women with cervical cancer were selected at Beijing Baiziwan Hemei Women and Children Hospital. They were classified into an observation group and a control group based on detection methods with 40 patients in each group. Liquid-based cytology test( LCT) combined with p16^(INK4a) was employed in the observation group using and LCT was employed in the control group. The cytologic diagnosis results were compared between the two groups and the consistency was compared with pathological detection results. Results There was no significant difference in diagnosis consistency between the two groups for atypical squamous cells( ASC) and no intraepithelial lesion or malignant lesion( NILM) and there were significant difference in diagnosis consistency between the two groups for squamous cell carcinoma( SCC),high-grade squamous intraepithelial lesion( HSIL) and low-grade squamous intraepithelial lesion( LSIL)( all P<0.05). There was no significant difference in diagnosis consistency between the two groups for cervical intraepithelial neoplasia( CIN) Ⅰ and inflammation( P>0.05).The difference in diagnosis consistency was statistically significant between the two groups for SCC,HSIL and LSIL( all P<0.05). Conclusion LCT combined with p16^(INK4a) examination showed diagnosis consistency for cervical cancer compared with pathological diagnosis. It is worthy of promotion and use to improve the early diagnosis rate of cervical cancer.